Niigata, Japan - The Department of Neurology at Niigata University has developed a new in silico method for evaluating the pathogenicity of missense variants using AlphaFold2 (MOVA). Rare variants in the causative gene of ALS are present in 10-30% of sporadic ALS cases, which highlights the need for accurate and efficient pathogenicity prediction methods. To predict the pathogenicity of the variants, in silico analysis methods are commonly used. In some ALS causal genes, the mutations are concentrated in specific regions, and the accuracy of pathogenicity prediction can be improved by considering the positional information of the variants. However, existing methods have not well considered information on the position of variants in the protein’s structure. MOVA was developed to address this issue and focuses on using positional information in the 3D structure to evaluate the pathogenicity of missense variants. The use of machine learning method, random forest, in the development of MOVA has also shown promising results. “The comparison of MOVA with existing in silico analysis methods, such as PolyPhen-2, CADD, REVEL, EVE, and AlphScore, demonstrates its potential in pathogenicity prediction. Combining MOVA with existing methods, such as REVEL and CADD, further improves performance beyond existing pathogenicity prediction methods alone. Moreover, MOVA also showed superior pathogenicity discrimination of hotspot mutations in the TARDBP and FUS genes. This highlights the importance of considering the positional information of variants in protein structures for improved pathogenicity prediction.” explain Dr. Hatano and Dr. Ishihara. The results of the study were published in the online edition of the journal BMC Bioinformatics on 2023.
END
MOVA: new method for evaluating the pathogenicity of missense variants using AlphaFold2
2023-06-13
(Press-News.org)
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
23Na MRI technique unleashes new approach for diagnosing diabetic kidney disease
2023-06-13
Niigata, Japan - The gold standard test for predicting the onset of diabetic kidney disease is albuminuria. However, detecting albuminuria alone has limited sensitivity and specificity in end-stage renal failure with a decreased estimated glomerular filtration rate. This is supported by several reports, which state that about half of the type 2 diabetes patients who developed kidney dysfunction showed no preceding albuminuria.
In this study, the authors propose the possibility of diagnosing tubular abnormalities in diabetic kidney disease at an early stage and connecting them to treatment by combining the evaluation of sodium concentration using 23Na MRI ...
Immune cell movement worse in older females, mice study finds
2023-06-13
Older female mice had more immune cells entering areas of the body where they shouldn’t according to a new study, demonstrating that sex differences contribute to age-related inflammation that needs to be considered in future research.
In a paper published in Journal of Leukocyte Biology today (Tuesday 13 June), at team of researchers led by Dr Myriam Chimen from the University of Birmingham have found that age significantly increases the number of immune cells entering the sack that holds major organs (peritoneal cavity) in female mice, when compared to young mice or older male mice.
The findings support previous studies that suggest ...
THE LANCET: First phase 3 trial of a chikungunya vaccine candidate finds it is generally safe and provokes an immune response
2023-06-13
Peer-reviewed / Randomised Controlled Trial / People
Study of healthy US adults found that a single dose of the VLA1553 vaccine candidate was generally safe, well tolerated and provokes an immune response.
After a single vaccination, the vaccine produced neutralizing antibody levels which are thought to protect against chikungunya disease in 99% (263/266) of participants.
Antibody levels declined 28 days after vaccination, but seroprotection persisted in more than 96% (233/242) participants after six months.
Most adverse events were moderate or mild and the authors say its safety profile is similar to other licensed vaccines
The VLA1553 vaccine candidate ...
The chatbot will see you now:
2023-06-13
Glasgow, UK: The informed consent process in biomedical research is biased towards people who can meet with clinical study staff during the working day. For those who have the availability to have a consent conversation, the time burden can be off-putting. Professor Eric Vilain, from the Department of Paediatrics, University of California, Irvine, USA, will tell the European Society of Human Genetics annual conference today (Tuesday 13 June) how results from his team’s study of the use of a chatbot (GIA – ‘Genetics Information Assistant’ ...
NHS policies on patient’s weight and access to hip replacement surgery are inappropriate, study finds
2023-06-13
Weight and body mass index (BMI) policies introduced by NHS commissioning groups in England are inappropriate and worsening health inequalities, according to a new study published in BMC Medicine today [13 June] that analysed nearly 490,000 hip surgeries. With one in ten people likely to need a joint replacement in their lifetime, many thousands of patients are directly affected by these policies.
Rules implemented by NHS clinical commissioning groups (CCGs) across England to change the access to hip and knee replacement surgery for patients who are overweight or obese have been in effect for over ten years. ...
A baking soda solution for clean hydrogen storage
2023-06-13
In a world of continuously warmer temperatures, a growing consensus demands that energy sources have zero, or next-to-zero, carbon emissions. That means growing beyond coal, oil, and natural gas by getting more energy from renewable sources.
One of the most promising renewable energy carriers is clean hydrogen, which is produced without fossil fuels.
It’s a promising idea because the most abundant element in the universe is hydrogen, found in 75 percent of all matter. Moreover, a hydrogen molecule has two paired atoms—Gemini twins that are both non-toxic and highly combustible.
Hydrogen’s combustive potential ...
Can this medication reverse MS? Brain biomarker shows it can
2023-06-13
A decade after UC San Francisco scientists identified an over-the-counter antihistamine as a treatment for multiple sclerosis, researchers have developed an approach to measure the drug’s effectiveness in repairing the brain, making it possible to also assess future therapies for the devastating disorder.
The researchers, led by physician-scientist Ari Green, MD, who together with neuroscientist Jonah Chan, PhD, first identified clemastine as a potential MS therapy, used MRI scans to study the drug’s impact on the brain of 50 participants in a clinical study.
In MS, patients lose myelin, the protective insulation around ...
The advances and promise of continuous glucose monitoring in diabetes management
2023-06-13
As adoption of Continuous Glucose Monitoring (CGM) continues to increase, there is a growing body of evidence supporting the use of this technology in improving diabetes outcomes for patients with Type 1 or Type 2 Diabetes. A new supplement in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) provides an excellent perspective of the past, present, and future of CGM. Click here to read the supplement now.
In the supplement Rickson et al. review the rapid pace in which diabetes technology has progressed and the implications for relying on rigorous and extensive timelines to publish randomized controlled trials to impact ...
Ochsner Health names new chief financial officer and treasurer
2023-06-13
NEW ORLEANS, La. – Ochsner Health has named Jim Molloy as the organization’s next Executive Vice President, Chief Financial Officer and Treasurer. A leader at Citi bringing decades of extensive experience in healthcare finance, Molloy will oversee the organization’s accounting, financial planning and analysis, reimbursement and revenue cycle functions, as well as managed care contracting and treasury. He will also play a pivotal role in the continued development and execution of ...
Low birthweight is independently linked to increased risk of type 2 diabetes, and a particular presentation including lower age at diagnosis
2023-06-13
T2D patients with lower birthweight also show higher use of diabetes drugs than those with normal birthweight, and a larger number of comorbidities including high blood pressure, at the time of diagnosis.
The first study is by Dr Rasmus Wibaek, Steno Diabetes Center Copenhagen, Herlev, Denmark, and Dr Allan Vaag, Steno Diabetes Center Copenhagen, and also Lund University, Malmö, Sweden, and colleagues.
This study included adults aged 30–60 years enrolled in the Danish Inter99 cohort in 1999–2001 (baseline examination), with information on birthweight from original birth records from 1939–1971 and without diabetes at baseline. Birth records were linked ...